<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287469</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR 749</org_study_id>
    <secondary_id>HSRRB A-9117.1</secondary_id>
    <secondary_id>GSK 304558/003 (HEV-003)</secondary_id>
    <secondary_id>IND 7815</secondary_id>
    <nct_id>NCT00287469</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.</brief_title>
  <official_title>A Phase II, Prospective, Randomized, Double-blind, Placebo Controlled, Field Efficacy Trial of a Candidate Hepatitis E Vaccine in Nepal.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a hepatitis E vaccine is safe and able to
      prevent symptomatic liver disease due to the hepatitis E virus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind, placebo-controlled with 2 study groups
      (vaccine and placebo). Three doses of the study vaccine are given according to a 0, 1, 6
      month schedule. Vaccine efficacy will be assessed by maintaining active surveillance for
      clinical hepatitis every 2 weeks and hospital based surveillance for the full duration of the
      trial. Total planned study population is 2000 eligible subjects (1000 in the vaccine group
      and 1000 in the placebo group). Total vaccinated cohort for the analysis of reactogenicity is
      200 (100 in the vaccine group and 100 in the placebo group).

      Volunteers who enroll will be followed for evidence of symptomatic liver disease for
      approximately 2 years, and those who become ill will be admitted to hospital for care.

      To evaluate safety, a randomly designated subset will be monitored for 7 days after each
      vaccination to solicit specific symptoms at the injection site and generally. Additionally,
      all adverse events will be collected for 30 days after each vaccine dose and all serious
      adverse events will be collected throughout the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2001</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 19, 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period</measure>
    <time_frame>14 days after dose 3 at 6 months</time_frame>
    <description>Percent of participants of definite hepatitis E by category and immunological markers (anti HEV) during the follow-up period.
Illness for at least 3 days comprised of at least 3 of the following symptoms: fatigue, loss of appetite, abdominal discomfort, right upper quadrant pain, nausea, vomiting
Peak of Alanine Aminotransferase (ALT) greater then 2.5 times the upper limit of normal (2.5 x 42 =105)
Percent of Participants = n x 100 / N</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants of Definite Hepatitis E Disease by Category During the Follow-up Period</measure>
    <time_frame>14 days after dose 2 until 14 days after dose 3</time_frame>
    <description>Percent of participants of definite hepatitis E and vaccine efficacy by category during the follow-up period
Illness for at least 3 days comprised of at least 3 of the following symptoms: fatigue, loss of appetite, abdominal discomfort, right upper quadrant pain, nausea, vomiting
Peak of Alanine Aminotransferase (ALT) greater then 2.5 times the upper limit of normal (2.5 x 42 =105)
Percent of participants = n x 100 / N</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Suspected, Definite, Probable and Not Confirmed Hepatitis E Disease Cases</measure>
    <time_frame>before dose 1 thru 14 days after dose 3</time_frame>
    <description>Number of suspected, definite, probable and not confirmed hepatitis E disease cases during surveillance period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2000</enrollment>
  <condition>Hepatitis</condition>
  <arm_group>
    <arm_group_label>20mcg Recombinant HEV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis E vaccine, recombinant (Sar 56 kDa)</intervention_name>
    <description>20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)</description>
    <arm_group_label>20mcg Recombinant HEV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PBS buffer placebo containing alum</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female 18 years of age or older at the time of the first vaccination.

          -  Written or oral witnessed (if the subject was illiterate) informed consent obtained
             from the subject

          -  Free of obvious health problems as established by medical history before entering into
             the study

          -  If the subject was female, she must have a negative serum pregnancy test within 48
             hours prior to each vaccination and must agree to avoid becoming pregnant during the
             course of vaccination and until 30 days after the last dose of vaccine.

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use
             during the study period.

          -  Administration of chronic (defined as more than 14 days) immunosuppressants or other
             immune modifying drugs within six months of vaccination. For corticosteroids, this
             will mean prednisone, or equivalent, * 0.5 mg/kg/day. Inhaled and topical steroids are
             allowed.

          -  Any chronic drug therapy to be continued during the study period with the exception of
             contraceptive agents, homeopathic remedies, vitamins, minerals and any other dietary
             supplements or other drug therapy at the discretion of the investigator.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days of the first dose of study vaccine, excluding tetanus toxoid or rabies
             vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection, as reported by the volunteer (testing
             for HIV will not be performed).

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Acute disease at the time of enrollment. Acute disease was defined as the presence of
             a moderate or severe illness with or without fever. All vaccines could be administered
             to persons with a minor illness such as diarrhea, mild upper respiratory infection
             with or without low-grade febrile illness, i.e., oral temperature &lt; 38.0°C (100.4°F).

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by history.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Pregnant female.

          -  History of chronic alcohol consumption (defined as the consumption of the equivalent
             of 4 or more 12 ounce beers 4 or more times a week) and/or intravenous drug abuse.

          -  Antibodies to rHEV (* 20 WR U/mL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mrigendra P Shrestha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Armed Forces Research Institute of Medical Sciences, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert M Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Institute of Research (WRAIR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shree Birendra Hospital</name>
      <address>
        <city>Kathmandu</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <reference>
    <citation>Worm HC, Schlauder GG, Brandstätter G. Hepatitis E and its emergence in non-endemic areas. Wien Klin Wochenschr. 2002 Aug 30;114(15-16):663-70. Review.</citation>
    <PMID>12602109</PMID>
  </reference>
  <reference>
    <citation>Worm HC, van der Poel WH, Brandstätter G. Hepatitis E: an overview. Microbes Infect. 2002 May;4(6):657-66. Review.</citation>
    <PMID>12048035</PMID>
  </reference>
  <reference>
    <citation>Emerson SU, Purcell RH. Running like water--the omnipresence of hepatitis E. N Engl J Med. 2004 Dec 2;351(23):2367-8.</citation>
    <PMID>15575050</PMID>
  </reference>
  <reference>
    <citation>Purcell RH. Hepatitis viruses: changing patterns of human disease. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2401-6. Review. Erratum in: Proc Natl Acad Sci U S A 1994 Sep 13;91(19):9195.</citation>
    <PMID>8146130</PMID>
  </reference>
  <reference>
    <citation>Worm HC, Wirnsberger G. Hepatitis E vaccines: progress and prospects. Drugs. 2004;64(14):1517-31. Review.</citation>
    <PMID>15233590</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 2, 2006</study_first_submitted>
  <study_first_submitted_qc>February 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <results_first_submitted>October 9, 2018</results_first_submitted>
  <results_first_submitted_qc>May 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2019</results_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis E</keyword>
  <keyword>clinical hepatitis</keyword>
  <keyword>vaccine</keyword>
  <keyword>efficacy</keyword>
  <keyword>Nepal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis E</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2000 subject were recruited by Royal Nepalese Army investigators at the Shree Birendra Hospital, Kathmandu from a well characterized population of Royal Nepalese Army military personnel stationed in the Kathmandu Valley and their family members and up to 5 US citizens residing in the Nepal.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
Placebo: PBS buffer placebo containing alum</description>
        </group>
        <group group_id="P2">
          <title>20mcg Recombinant HEV</title>
          <description>20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
Hepatitis E vaccine, recombinant (Sar 56 kDa): 20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1000"/>
                <participants group_id="P2" count="1000"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="780"/>
                <participants group_id="P2" count="786"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="214"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>moved from area</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
Placebo: PBS buffer placebo containing alum</description>
        </group>
        <group group_id="B2">
          <title>20mcg Recombinant HEV</title>
          <description>20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
Hepatitis E vaccine, recombinant (Sar 56 kDa): 20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1000"/>
            <count group_id="B2" value="1000"/>
            <count group_id="B3" value="2000"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Male and Female participants add up to the total number for each group: Placebo (1000) and 20mcg Recombinant HEV (1000).</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Female</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="12.69"/>
                    <measurement group_id="B2" value="28.0" spread="8.29"/>
                    <measurement group_id="B3" value="29.6" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="996"/>
                    <count group_id="B2" value="996"/>
                    <count group_id="B3" value="1992"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="6.12"/>
                    <measurement group_id="B2" value="25.2" spread="6.34"/>
                    <measurement group_id="B3" value="25.2" spread="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1000"/>
                    <count group_id="B2" value="1000"/>
                    <count group_id="B3" value="2000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="996"/>
                    <measurement group_id="B2" value="996"/>
                    <measurement group_id="B3" value="1992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Nepal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1000"/>
                    <count group_id="B2" value="1000"/>
                    <count group_id="B3" value="2000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1000"/>
                    <measurement group_id="B2" value="1000"/>
                    <measurement group_id="B3" value="2000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period</title>
        <description>Percent of participants of definite hepatitis E by category and immunological markers (anti HEV) during the follow-up period.
Illness for at least 3 days comprised of at least 3 of the following symptoms: fatigue, loss of appetite, abdominal discomfort, right upper quadrant pain, nausea, vomiting
Peak of Alanine Aminotransferase (ALT) greater then 2.5 times the upper limit of normal (2.5 x 42 =105)
Percent of Participants = n x 100 / N</description>
        <time_frame>14 days after dose 3 at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>20mcg Recombinant HEV</title>
            <description>20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
Hepatitis E vaccine, recombinant (Sar 56 kDa): 20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
Placebo: PBS buffer placebo containing alum</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period</title>
          <description>Percent of participants of definite hepatitis E by category and immunological markers (anti HEV) during the follow-up period.
Illness for at least 3 days comprised of at least 3 of the following symptoms: fatigue, loss of appetite, abdominal discomfort, right upper quadrant pain, nausea, vomiting
Peak of Alanine Aminotransferase (ALT) greater then 2.5 times the upper limit of normal (2.5 x 42 =105)
Percent of Participants = n x 100 / N</description>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="1000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Jaundice; IgM ≥ 100 WR U/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.3" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jaundice; total lg ≥ 2500 WR U/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jaundice; IgM≥100 WR U/mL or total lg≥2500 WR U/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                    <measurement group_id="O2" value="7.0" lower_limit="5.4" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Illness; IgM ≥ 100 WR U/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Illness; total lg ≥ 2500 WR U/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Illness; IgM≥100 WR U/mL or total lg≥2500 WR U/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jaun/Ill; IgM≥100 WR U/mL or total lg≥2500 WR U/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                    <measurement group_id="O2" value="7.4" lower_limit="5.7" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants of Definite Hepatitis E Disease by Category During the Follow-up Period</title>
        <description>Percent of participants of definite hepatitis E and vaccine efficacy by category during the follow-up period
Illness for at least 3 days comprised of at least 3 of the following symptoms: fatigue, loss of appetite, abdominal discomfort, right upper quadrant pain, nausea, vomiting
Peak of Alanine Aminotransferase (ALT) greater then 2.5 times the upper limit of normal (2.5 x 42 =105)
Percent of participants = n x 100 / N</description>
        <time_frame>14 days after dose 2 until 14 days after dose 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>20mcg Recombinant HEV</title>
            <description>20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
Hepatitis E vaccine, recombinant (Sar 56 kDa): 20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
Placebo: PBS buffer placebo containing alum</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants of Definite Hepatitis E Disease by Category During the Follow-up Period</title>
          <description>Percent of participants of definite hepatitis E and vaccine efficacy by category during the follow-up period
Illness for at least 3 days comprised of at least 3 of the following symptoms: fatigue, loss of appetite, abdominal discomfort, right upper quadrant pain, nausea, vomiting
Peak of Alanine Aminotransferase (ALT) greater then 2.5 times the upper limit of normal (2.5 x 42 =105)
Percent of participants = n x 100 / N</description>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="1000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Jaundice; IgM ≥ 100 WR U/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.4" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jaundice; total Ig ≥ 2500 WR U/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jaundice; IgM≥100 WR U/mL or total lg≥2500 WR U/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.4" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Illness; ImG ≥ 100 WR U/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Illness; total Ig ≥ 2500 WR U/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jaun/Ill; IgM≥100 WR U/mL or total lg≥2500 WR U/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.4" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Suspected, Definite, Probable and Not Confirmed Hepatitis E Disease Cases</title>
        <description>Number of suspected, definite, probable and not confirmed hepatitis E disease cases during surveillance period</description>
        <time_frame>before dose 1 thru 14 days after dose 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
Placebo: PBS buffer placebo containing alum</description>
          </group>
          <group group_id="O2">
            <title>20mcg Recombinant HEV</title>
            <description>20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
Hepatitis E vaccine, recombinant (Sar 56 kDa): 20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Suspected, Definite, Probable and Not Confirmed Hepatitis E Disease Cases</title>
          <description>Number of suspected, definite, probable and not confirmed hepatitis E disease cases during surveillance period</description>
          <units>Number of Hepatitis E Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="1000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any acute hep cases: before dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hep cases: within 14 days after dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hep cases: between 14 days after dose 1 and 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hep cases: within 14 days after dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hep cases: between 14 days after dose 2 and 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hep cases: within 14 days after dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hep cases: from 14 days after dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hep cases: Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite hepE cases: before dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite hepE cases: within 14 days after dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite hepE cases: btwn 14dys after dose 1 and 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite hepE cases: within 14 days after dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite hepE cases: btwn 14dys after dose 2 and 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite hepE cases: within 14 days after dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite hepE cases: from 14 days after dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definate hepE cases: Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable hepE cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not confirmed hepE: before dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not confirmed hepE: within 14 days after dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not confirmed hepE: btwn 14dys after dose 1 and 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not confirmed hepE: within 14 days after dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not confirmed hepE: btwn 14dys after dose 2 and 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not confirmed hepE: within 14 days after dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not confirmed hepE: from 14 days after dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not confirmed hepE: total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Within 31 days (days 0-30) post-vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
Placebo: PBS buffer placebo containing alum</description>
        </group>
        <group group_id="E2">
          <title>20mcg Recombinant HEV</title>
          <description>20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
Hepatitis E vaccine, recombinant (Sar 56 kDa): 20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="1000"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gilbert's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Corneal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Carcadian rhythm sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Gravitational oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic liver disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hepatomegal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Jaundice hepatocellular</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Ascariass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Cestode infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dermatitis infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Encephalitis japanese b</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" events="81" subjects_affected="81" subjects_at_risk="1000"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hookworm infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hymenolepiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Mumps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Neurocysticercosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Paratyphoid fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1000"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Respiratory tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Salmonella bacteraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Sexually transmitted disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="1000"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1000"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1000"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Blast injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Polytraumatism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Costochandritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Intervertebrial disc protrution</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Rheumatic fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Sacroilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arachnoid cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Cerebellar ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal septum</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Vocal cord thickening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Eczema nummular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anal fistula excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Haemorrhoid operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Vasectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="226" subjects_at_risk="1000"/>
                <counts group_id="E2" subjects_affected="229" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1000"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="1000"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1000"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pericoronitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Salivary gland mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1000"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Injection site anaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1000"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="1000"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice hepatocellular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Encephalitis japanese b</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Helminthic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hepatitis e</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="1000"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Paratyphoid fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Salmonella bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1000"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1000"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1000"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Post procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1000"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="1000"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Neophrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1000"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Lichenoid keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Vasectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1000"/>
              </event>
              <event>
                <sub_title>Wart excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1000"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mrigendra P. Shrestha MD</name_or_title>
      <organization>Armed Forces Research Institute of Medical Services</organization>
      <phone>662-644-4888</phone>
      <email>shrestham@afrims.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

